Hong Gul Cheong, CEOThe best part is that the antibodies are produced through natural biological processes. IgY is derived from immunizing poultry, collecting their eggs and extracting antibodies from the yolks. It’s administered orally, allowing it to act directly in the gastrointestinal tract, where many infections begin due to pathogen entry through food. The antibodies are especially valuable for offering a noninvasive, targeted response.
Nanobodies, on the other hand, are derived from camelids like llamas and alpacas, which naturally produce a unique form of antibody. These are about one-tenth the size of conventional antibodies, penetrating tissues more effectively and delivering precise, injectable treatments. The efficacy lasts 30 days with a single injection, a far more long-acting protection with minimal intervention.
“Managing every step in-house, from pure antigen selection to large-scale manufacturing, within our Korea Good Manufacturing Practice-certified facility, we ensure uncompromised oversight across the full development lifecycle, translating scientific rigor into reliable, market-ready solutions,” says Hong Gul Cheong, CEO.
-
Managing every step in-house, from pure antigen selection to large-scale manufacturing, within our Korea Good Manufacturing Practice-certified facility, we ensure uncompromised oversight across the full development lifecycle, translating scientific rigor into reliable, market-ready solutions.
These advances are making a difference in the field, making it possible to prevent diseases such as calf diarrhea, porcine reproductive and respiratory syndrome (PRRS), porcine epidemic diarrhea (PED) and other high-impact conditions affecting livestock health and farm productivity.
ADBIOTECH is the first company to develop nanobody-based antibodies targeting deadly viruses and bacteria in livestock, applying a technology still under investigation in human medicine to address critical gaps in animal health. Nanobody development suggests new alternatives for treating deadly diseases in industrial animals. In collaboration with global partners, the company is scaling production and expanding access to ensure these life-saving technologies reach farms worldwide.
From Antibodies to Environmental Impact
Today, as the world becomes more conscious of environmental sustainability, ADBIOTECH has turned its scientific expertise toward a pressing environmental challenge—food waste.
ADBIOTECH spent two years developing a patented microbial agent that transforms how food waste is handled at home. Rather than relying on energy-intensive grinding or heating, its innovation uses biologically active microorganisms to quietly and cleanly decompose food scraps into water, carbon dioxide and trace biomass. It seamlessly fits into the rhythm of urban living, meeting the needs of eco-conscious households looking for cleaner, smarter ways to live.
Instead of selling appliances as one-off products, ADBIOTECH partnered with South Korea’s largest global home appliance company, LG Electronics, to launch a subscription-based system. Users replace the microbial agent twice a year, ensuring consistent performance while building long-term trust. This recurring model is expected to generate ₩15 billion annually, turning a green habit into a profitable engine for growth. With only five percent of households using food waste disposers today, the company is poised to scale across more than four million homes—proving that environmental innovation, when rooted in science and supported by smart business, can make sustainability not just possible, but inevitable.
Whether advancing immune health in livestock or reshaping how we manage food waste at home, ADBIOTECH is proving that science-driven innovation can meet the moment—improving lives and building a more sustainable future, one smart solution at a time.
Immune Antibody Development Info
Why is ADBiotech recognized among Top Immune Antibody Development Services providers?
ADBiotech has gained recognition in Immune Antibody Development Services due to its specialized focus on designing and producing antibodies tailored for immune research and therapeutic applications. The company supports the discovery and engineering of antibody candidates with strong specificity and binding performance, which are essential in modern immunology and biologics research. Its contribution to Immune Antibody Development Services is rooted in enabling researchers and biopharmaceutical teams to accelerate antibody discovery while maintaining scientific precision in early-stage development workflows.
What differentiates ADBiotech in Immune Antibody Development Services?
A key differentiator for ADBiotech in Immune Antibody Development Services is its emphasis on custom antibody generation strategies aligned with immune-target validation. Instead of offering standardized outputs, it focuses on tailored development approaches that align with specific antigen targets and research goals. This ensures higher relevance of generated antibodies for downstream applications. Its Immune Antibody Development Services are structured to support both exploratory research and translational pipelines, helping bridge early discovery with applied biomedical use cases.
How does ADBiotech support researchers in antibody development projects?
ADBiotech supports research teams through a structured workflow under its Immune Antibody Development Services that includes antigen design consultation, antibody screening and validation support. It helps refine target selection and ensures that antibody candidates meet required specificity and affinity thresholds. This collaborative model allows researchers to reduce iteration cycles and improve efficiency in identifying viable immune-targeting antibodies. Its Immune Antibody Development Services are designed to integrate smoothly into academic, biotech and pharmaceutical research environments.
How do Immune Antibody Development Services from ADBiotech create scientific value?
Immune Antibody Development Services from ADBiotech create value by improving the precision and reliability of antibody discovery outcomes. The company focuses on generating antibody candidates that demonstrate strong immune recognition and functional stability, which is critical for downstream experimental success. By applying structured validation methods, it helps reduce variability in early research stages. This enhances reproducibility and ensures that immune-focused studies are supported by well-characterized biological tools.
What role does innovation play in ADBiotech’s Immune Antibody Development Services?
Innovation is central to Immune Antibody Development Services at ADBiotech, particularly in how it approaches antibody selection and optimization. The company integrates modern screening techniques and immune profiling insights to refine antibody performance. This allows it to support the development of more targeted and effective immune research tools. Its innovation-driven approach ensures that Immune Antibody Development Services remain aligned with evolving requirements in immunotherapy and biomedical research.
Why are Immune Antibody Development Services from ADBiotech relevant to modern biomedical research?
Immune Antibody Development Services from ADBiotech are increasingly relevant as biomedical research shifts toward targeted therapies and precision immunology. The demand for highly specific antibodies that can accurately interact with immune pathways continues to grow. The company supports this need by delivering antibody development solutions that improve target accuracy and experimental reliability. Its Immune Antibody Development Services therefore play a supportive role in advancing both basic immunology research and translational therapeutic development.
